{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-072900","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.772142+00:00","generated_at":"2026-05-17T21:52:51.764195+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel completes enrollment (last patient last visit) in SERENITY At-Home Phase 3 trial for BXCL501","bullets":["SERENITY At-Home Phase 3 safety trial for BXCL501 120 mcg to treat acute agitation in bipolar/schizophrenia.","Enrolled >200 patients across 22 sites; no single site >11% of total patients.","Patient distribution balanced between bipolar disorders and schizophrenia.","Collected data from >2,200 agitation episodes; topline results expected in August 2025.","Topline results expected to be announced this month."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-072900","json":"https://secwatch.observer/filing/0001104659-25-072900.json","markdown":"https://secwatch.observer/filing/0001104659-25-072900.md","text":"https://secwatch.observer/filing/0001104659-25-072900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925072900/0001104659-25-072900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925072900/tm2522315d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:52:51.764195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}